Immunovant stock: IMVT-1402 RA result sets up FDA path decision

Immunovant reported on Monday, November 9, 2026, that its IMVT-1402 600 mg dose met the primary endpoint in a potentially registrational trial for difficult-to-treat rheumatoid arthritis. According to the company's press release, 92.5 percent of patients on the 600 mg dose maintained an ACR20 response at Week 28, compared with 75.6 percent on placebo.

Higher Dose Clears Trial Endpoint

The result came from the second period of a randomized-withdrawal study after an open-label lead-in. The 300 mg dose did not differ from placebo on the same measure, while exploratory ACR50 results favored the 600 mg dose. Immunovant said the treatment was generally well tolerated during the period, with no serious adverse events, Grade 3 or higher treatment-emergent adverse events, or treatment discontinuations reported in any study arm.

Regulatory And Pipeline Milestones

Immunovant plans discussions with the U.S. Food and Drug Administration later this year on the development path for difficult-to-treat rheumatoid arthritis. The company expects topline results from potentially registrational IMVT-1402 trials in Graves' disease and myasthenia gravis in 2027, followed by data in chronic inflammatory demyelinating polyneuropathy in 2028.

The company also said it is unlikely to advance IMVT-1402 further in Sjogren's disease beyond the ongoing, fully enrolled Phase 2 trial. That decision narrows the development focus as management concentrates resources on the remaining programs.

Quarterly Loss Narrows

For the fiscal second quarter ended September 30, 2026, Immunovant reported a net loss of 97.2 million US dollars, or 0.47 US dollars per share, compared with a loss of 126.5 million US dollars, or 0.73 US dollars per share, a year earlier. Research and development expense fell to 85.0 million US dollars, while general and administrative expense increased to 19.1 million US dollars as pre-commercial activity expanded. Cash and cash equivalents stood at 722.3 million US dollars at quarter-end, which the company said supports its current plan through a potential Graves' disease launch.

Immunovant stock is listed on Nasdaq under the ticker IMVT.

Immunovant Key Facts

• Company: Immunovant, Inc.
• Ticker: IMVT
• Exchange: Nasdaq
• Update date: November 9, 2026
• Reporting period: Fiscal second quarter ended September 30, 2026
• Focus: IMVT-1402 and autoimmune diseases

The broader U.S. market backdrop can be followed in the S&P 500 topic.

For investors, the next major milestones are the planned FDA discussions on the rheumatoid arthritis program and clinical readouts in Graves' disease and myasthenia gravis. The company says its remaining development timelines are on track.